Novel pyrazolopiperazinone- and pyrrolopiperazinone-based MCH-R1 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 3, 2007, Pages 657-661

  Meyers, Kenneth M ^a   Méndez Andino, José ^a   Colson, Anny Odile ^a   Hu, X Eric ^a   Wos, John A ^a   Mitchell, Maria C ^a   Hodge, Karen ^a   Howard, Jeremy ^a   Paris, Jennifer L ^a   Dowty, Martin E ^a   Obringer, Cindy M ^a   Reizes, Ofer ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

5HT 2C receptor; MCH R1 antagonists; Melanin concentrating hormone; Obesity; Pyrazolopiperazinone; Pyrrolopiperazinone

Indexed keywords

MELANIN CONCENTRATING HORMONE; MELANIN CONCENTRATING HORMONE ANTAGONIST; PYRAZOLE DERIVATIVE; PYRAZOLOPIPERAZINONE; PYRROLOPIPERAZINONE; UNCLASSIFIED DRUG;

ARTICLE; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS;

CACO-2 CELLS; HUMANS; INDICATORS AND REAGENTS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PIPERAZINES; PYRAZOLES; PYRROLES; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SOMATOSTATIN;

EID: 33846231078     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.10.096     Document Type: Article

References (26)

1. The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity 2001, Public Health Service: Office of the Surgeon General, US Department of Health and Human Sevices: Rockville, MD, 2001; www.surgeongeneral.gov/topics/obesity.
2. Powell D.R. Obesity reviews 7 (2006) 89
3. Fong T.M. Expert Opin. Investig. Drugs 14 (2005) 243
4. Heal D.J., Rowley H.L., and Jackson H.C. Progress in obesity research 9 (2003) 260
5. Dyke H.J., and Ray N.C. Expert Opin. Ther. Patents 15 (2005) 1303
6. Carpenter A.J., and Hertzog D.L. Expert Opin. Ther. Patents 12 (2002) 1639
7. Kowalski T.J., and McBriar M.D. Expert Opin. Investig. Drugs 13 (2004) 1113
8. Receveur J.M., Bjurling E., Ulven T., Little P.B., Norregaard P.K., and Hogberg T. Bioorg. Med. Chem. Lett. 14 (2004) 5075
9. Shearman L.P., Camacho R.E., Sloan S.D., Zhou D., Bednarek M.A., Hreniuk D.L., Feighner S.D., Tan C.P., Howard A.D., Van der Ploeg L.H., MacIntyre D.E., Hickey G.J., and Strack A.M. Eur. J. Pharmacol. 475 (2003) 37
10. Kanuma K., Omodera K., Nishiguchi M., Funakoshi T., Chki S., Semple G., Tran T.-A., Kramer B., Hsu D., Casper M., Thomsen B., and Sekiguchi Y. Bioorg. Med. Chem. Lett. 15 (2005) 3853
11. Souers A.J., Gao J., Brune M., Bush E., Wodka D., Vasudevan A., Judd A.S., Mulhern M., Brodjian S., Dayton B., Shapiro R., Hernandez L.E., Marsh K.C., Sham H.L., Collins C.A., and Kym P.R. J. Med. Chem. 48 (2005) 1318
12. Ulven T., Little P.B., Receveur J.-M., Frimurer T.M., Rist Ø., Nørregaard P.K., and Högberg T. Bioorg. Med. Chem. Lett. 16 (2006) 1070
13. Ulven T., Frimurer T.M., Receveur J.-M., Little P.B., Rist Ø., Nørregaard P.K., and Högberg T. J. Med. Chem. 48 (2005) 5684
14. Palani A., Shapiro S., McBriar M.D., Clader J.W., Greenlee W.J., Spar B., Kowalski T.J., Farley C., Cook J., van Heek M., Weig B., O'Neill K., Graziano M., and Hawes B.E. J. Med. Chem. 48 (2005) 4746
15. Huang C.Q., Baker T., Schwarz D., Fan J., Heise C.E., Zhang M., Goodfellow V.S., Markison S., Gogas K.R., Chen T., Wang X.-C., and Zhu Y.-F. Bioorg. Med. Chem. Lett. 15 (2005) 3701
16. Méndez-Andino, J. L.; Colson, A.-O.; Meyers, K. M.; Mitchell, M. C.; Hodge, K. M.; Howard, J. M.; Ackley, D. C.; Holbert, J. K.; Mittelstadt, S. W.; Dowty, M. E.; Obringer, C. M.; Suchanek, P; Reizes, O.; Hu, X. E.; Wos, J. A. Bioorg. Med. Chem., submitted for publication.
17. Mieling, G. E.; Mieling, K. K.; Bush, R. D.; Colson, A.-O. US 2005170433 A1 2005.
18. Colson A.-O., Perlman J.H., Smolyar A., Gershengorn M.C., and Osman R. Biophys. J. 74 (1998) 1087
19. Askew B.C., McIntyre C.J., Hunt C.A., Claremon D.A., Gould R.J., Lynch R.J., and Armstrong D.J. Bioorg. Med. Chem. Lett. 5 (1995) 475
20. i) and maximal efficacy were determined and used to define structure-activity relationship.
21. 3H] mesulergine and excess 10 μM mianserin (ICN). After incubating the mixture at room temperature for 60 min, bound mesulergine was separated from unbound mesulergine by filtration through glass fiber B filter (GF/B) plates (Millipore). Bound radioactive mesulergine was detected using a scintillation counter.
22. Artursson P., Palm K., and Luthman K. Advanced Drug Delivery Reviews 46 (2001) 27
23. Within our MCH program, we observed that compounds predicted to transport passively across the blood-brain barrier in the Caco-2 assay usually promoted statistically significant weight loss in our 4-day mDIO model, and displayed [brain]/[serum] > 2. Compounds predicted efflux substrates did not show in vivo activity and displayed [brain]/[serum] < 1.
24. Please refer to: Meyers, K. M.; Méndez-Andino, J. L.; Colson, A. O.; Warshakoon, N. C.; Wos, J. A.; Mitchell, M. C.; Hodge, K. M.; Howard, J. M.; Ackley, D. C; Holbert, J. K.; Mittelstadt, S. W.; Dowty, M. E.; Obringer, C. M.; Ofer Reizes, O.; Hu, X. E. Bioorg. Med. Chem. Lett. 2006, 16, in press.
25. Barker P., Gendler R., and Rapoport H. J. Org. Chem. 43 (1978) 4849
26. West C.T., Donnelly S.J., Kooistra D.A., and Doyle M.P. J. Org. Chem. 15 (1973) 2675